Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAJ85O)

Drug Name

VDA-1102 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Actinic keratosis	EK90.0	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tissue kallikrein (KLK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avoralstat	DM5YHU2	Hereditary angioedema	4A00.14	Phase 2/3	[3]
JNJ-69086420	DM6VR13	Prostate cancer	2C82.0	Phase 1	[4]
JNJ-78278343	DM27FAN	Prostate cancer	2C82.0	Phase 1	[5]
JNJ-75229414	DMV6XBC	Prostate cancer	2C82.0	Phase 1	[6]
Dermolastin	DM6WSU2	Atopic dermatitis	EA80	Discontinued in Phase 2	[7]
DM-107	DMRYQVJ	Atopic dermatitis	EA80	Investigative	[8]
hK2p01 derivative KLK2 inhibitor	DME13RQ	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hexokinase-2 (HK2)	TTK02H8	HXK2_HUMAN	Modulator	[1]
Tissue kallikrein (KLK2)	TTJLNAW	KLK2_HUMAN	Modulator	[2]
Voltage-dependent anion channel (VDAC)	TTPZI04	NOUNIPROTAC	Modulator	[2]
Voltage-dependent anion-selective channel 1 (VDAC1)	TTAMKGB	VDAC1_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Clinical pipeline report, company report or official report of Vidac Pharma.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	ClinicalTrials.gov (NCT04644770) A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer. U.S. National Institutes of Health.
5	ClinicalTrials.gov (NCT04898634) A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer. U.S.National Institutes of Health.
6	ClinicalTrials.gov (NCT05022849) A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health.
7	Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2372).
9	Novel peptide inhibitors of human kallikrein 2. J Biol Chem. 2006 May 5;281(18):12555-60.